Completed PHASE3 INTERVENTIONAL 2-arm NCT00445185

Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™

Sponsor: Henogen

Conditions Hepatitis B

Interventions Fendrix vaccine Henogen HB vaccine

Updated 6 times since 2017 Last updated: Nov 18, 2009 Started: Mar 31, 2007 Primary completion: Jul 31, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hepatitis B and is currently completed. Henogen leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henogen

Data source: Henogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Ath, Belgium , Baudour, Belgium , Brussels, Belgium , Budapest, Hungary , Charleroi, Belgium , Ghent, Belgium , Győr, Hungary , Jihlava, Czechia , Kistarcsa, Hungary and 9 more locations